DIGITAL HEALTHCARE, MEDICAL DEVICES
mPulse Mobile, | December 16, 2022
mPulse Mobile, a leader in conversational AI and digital engagement solutions for the healthcare industry, announced the launch of new content capabilities and streaming courses that address health literacy barriers in a consumer-friendly format.
Several solution advances continue mPulse’s focus on integrating streaming content into digital health engagement strategies, creating an industry-leading combination of conversational AI that drives two-way SMS messaging campaigns and powerful health streaming content to engage, delight, and move consumers to adopt healthy behaviors.
“Stories” Video Format
mPulse launched the stories video format to deliver more impactful content experiences in consumer-focused outreach programs. The format adapts video “stories” commonly seen in social media platforms like TikTok and Instagram Reels to deliver captivating content on important healthcare topics. mPulse’s Health Activation Platform tailors the stories content to the individual to address important engagement challenges such as medication adherence, gaps in care, and health plan navigation.
“These new video capabilities are proof that mPulse Mobile continues to pioneer category-defining member engagement technology. Our highly tailored, consumer focused content is a powerful tool that creates culturally sensitive digital experiences to address health disparities, encourage healthy behaviors, and drive member outcomes. The stories format allows us to be more impactful when consumers engage, and our initial results show they have a significant impact on program goals.”
Bob Farrell, CEO of mPulse Mobile
The format drives increased engagement and improved health outcomes among targeted populations.
mPulse deployed the stories format in a diabetes eye-screening outreach program. The program included 200,000 Medicare Advantage members, with a subset of 100,000 members receiving the streaming content, delivered in a stories format. This cohort showed a 274% higher Call to Action completion rate than members who did not receive the stories-formatted content.
Leveraging conversational outreach, consumers are prompted on the issues that might be preventing them from completing a given action. When they respond via text to identify a barrier, tailored streaming content is delivered instantly and in real-time via an embedded link to address the barrier.
New Health Educational Courses
mPulse has also launched new streaming health courses that address key health issues and improve health literacy in a consumer-friendly digital format. Produced with proven learning techniques and behavioral science, these courses allow healthcare organizations to extend the digital experience from initial outreach to deep, relationship-building experiences.
“Our product strategy aims to offer the most effective technology at delivering health engagement, and core to mPulse’s value is meaningful digital content, which elevates engagement experiences to a new level,” said Sanjeev Sawai, Chief Product and Technology Officer at mPulse Mobile. “Members are in need of better educational content that they find engaging and worth their time. We use short, captivating content to get members' attention and motivate them to act in healthy ways - ways that help them build their health literacy, prevent diseases, manage conditions, and foster wellbeing. Our approach offers innovative frictionless ways to encourage members to engage deeply in their own health and healthcare.”
About mPulse Mobile
mPulse Mobile is reimagining health engagement to inspire healthier lives and deeper relationships between healthcare organizations and their consumers. A leading healthcare Conversational AI platform combines with award-winning health education for the streaming age to deliver tailored digital health engagement that nurtures, educates, and activates healthcare consumers. With more than a decade of experience, 150+ healthcare customers and 1 billion conversations annually, mPulse Mobile has the data, the expertise, and the solutions to drive healthy behavior change.
Florence Healthcare | November 18, 2022
Florence Healthcare™, a clinical research technology company headquartered in Atlanta, Georgia, announced the completion of a year-long third-party study on the impact of Site Enablement Platforms™ on clinical research timelines and costs.
The study by Marketcap Consulting is the first to compare how traditional site management approaches differ from site-first Site Enablement Platforms. The study looked at the impact of traditional sponsor portals and new Site Enablement Platforms on research sponsor and Contract Research Organization study timelines and budgets.
“Pharma sponsors and CROs realize the importance of enabling sites to do their best work - but only recently have they discovered that traditional site portals are more hindrance than help. Yet, these organizations weren't able to measure the true impact of switching to a Site Enablement Platform. This year-long study aimed to fix that and highlight how linking fragmented workflows accelerates the full lifecycle of clinical trials.”
Ryan Jones, CEO of Florence Healthcare
Site enablement is a new technology category that prioritizes the needs of the site, a major shift from past technology that only looked at the experience of the sponsor. These platforms, including Florence Healthcare’s SiteLink™, insist on ease-of-use and ease-of-setup for the site, quality support, and simplified integrations. SiteLink works in conjunction with eBinders™, an electronic Investigator Site File solution used by over 12,000 research sites in 45 countries.
About the Study
Marketcap Consulting conducted interviews with clinical research operations leaders harnessing SiteLink, examined timelines and study costs, and analyzed the impact across the sites in the study. On average, the team found that SiteLink accelerated study start-up by four weeks and study close-out by two weeks at every site. For a 50-site study, this six-week acceleration reduced cash burn by one million dollars.
“We can see a clear positive impact on study timelines and cash burn when research sponsors and CROs implement Site Enablement Platforms,” said Joel White, founder of Marketcap Consulting. “This early study reveals that by enabling sites to do their best work, the clinical research industry unlocks value across the full research cycle.”
“While the financial impact of switching to SiteLink makes investing in site enablement an easy choice for sponsors and CROs, it’s really the acceleration of studies that gets our team at Florence Healthcare excited,” said Jones. “We aim to double the output of research teams by the end of the decade, and enabling sites is the way to do it.”
About Florence Healthcare
Florence Healthcare’s clinical trial software helps more than 12,000 research sites in 45 countries manage their documents, data, and workflows. The Florence Healthcare™ platform also provides remote access so sponsors and Contract Research Organizations can collaborate with their sites around the world. Florence Healthcare users now perform 5.8 million remote monitoring activities each month.
HEALTH TECHNOLOGY, MEDICAL DEVICES
19Labs | December 20, 2022
In cooperation with the Ministry of Health and the Georgetown Public Hospital Corporation a telemedicine pilot program with GALE eClinics was launched in four remote areas of Guyana.
"We have reached a milestone and begin a journey that has the potential to transform health."
Dr. Leslie Ramsammy, GPHC Board Chairman
During the Telemedicine Launch, 19Labs CEO, Ram Fish, joined Guyana's Health Minister, Dr. Frank Anthony, in Masakenari, or as it is better known locally, Gunns Village. They were welcomed by the village Toshao, Paul Chekema, and the village residents. Using the newly installed eClinic system, Gunns was able to connect to the Georgetown Public Hospital and the three other villages that form part of this pilot program.
The program's purpose is to provide equitable healthcare to all of Guyana's citizens. This keeps in line with the vision of Guyana's President, Dr. Ali, of creating a 'world-class' healthcare system for Guyana. Dr. Ramsammy, began the launch by saying:
"Our ambition is to improve health care for all of our people, and as we understand that we can't put…a Georgetown public-level hospital in every village, we believe that citizens, in every part of the country, could get access to basic healthcare…We have reached a stage this morning, where we could launch Guyana's national telemedicine program."
One of the major challenges in achieving such a vision is the remote locations with the lack of connectivity. Gunns Village is a 5-day boat and land trek during the rainy season when planes cannot use the local airstrip. 19Labs is proud to provide a solution as the four health posts that are part of this pilot are now connected to the world through the internet over satellite.
With the GALE eClinic Telemedicine units, even the most isolated village now has access to top-quality medical care. In a very short time, Gunns went from an area that had no connectivity, electricity, and little medical equipment, to the ability to instantly connect to the healthcare and staff of the Georgetown Public Hospital. Dr. Anthony said:
"With the technology we have now installed, this particular health center has a full complement of internet-enabled devices which we will…be able to do ultrasounds, ECGs, and a whole host of other things to help to assess the patient."
GALE eClinics replicate the full clinical experience providing and filling the need for both general health and specialty care including prenatal, OBGYN, maternal, cardiac, and chronic condition management. Our partnership goes beyond a one-time fix. The local communities now have access to more opportunities. Ram Fish said:
"This goes even beyond just health care, [this transforms communities]. The equity that it brings to us also opens the eyes of people and places to different cultures, and different ways of doing things…It's about empowering with technology local young women and men who really become the centers of the communities beyond just health…This is the beginning of a journey…We will expand and work together to really make healthcare equitable across Guyana and beyond."
19Labs is the creator of GALE, Next Generation Point-of-Care platform for pharmacies, schools, and rural communities. GALE brings together cutting-edge diagnostic technologies from industry leaders like Zoom, Elo, Amwell, Eko, Samsung Mobile, MIR, Omron, Viasat, and many others in one smart, efficient, and cost-effective platform. It was designed from the ground up to be operated by non-healthcare professionals, in locations with limited infrastructure and optimized for low bandwidth and intermittent connectivity.
ASEP Medical Holdings Inc | November 25, 2022
Asep Medical Holdings Inc. is pleased to announce that, for recruitment, incentivization, and retention purposes, it has granted to certain officers and advisors an aggregate of 1,080,000 stock options to purchase up to 1,080,000 common shares of the Company of which 200,000 are exercisable at a price of $0.30 per Share until September 29, 2032, 200,000 are exercisable at a price of $0.30 per share until October 1, 2032, and 680,000 are exercisable at a price of $0.30 per share until November 24, 2032.
ABOUT ASEP MEDICAL HOLDINGS INC
Asep Inc. is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs. The Company is a consolidation of two existing private companies that are both in the advanced development of both proprietary diagnostic tools, enabling the early and timely identification of severe sepsis as well as broad-spectrum therapeutic agents to address multidrug-resistant biofilm infections.
Sepset Biosciences Inc. is developing a diagnostic technology that involves a patient gene expression signature that predicts severe sepsis, one of the significant diseases leading to antibiotic failure since antibiotics are the primary treatment for sepsis. Despite this, sepsis is responsible for nearly 20% of all deaths on the planet. The semester test is a blood-based gene expression assay that is straightforward to implement, and results are obtained in about an hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in enabling diagnosis of severe sepsis within 1-2 hours of first clinical presentation while other diagnostics only provide diagnosis after 24-36 hours. Asep Inc. believes this will enable critical early decisions to be made by physicians regarding appropriate therapies and reduce overall morbidity and mortality due to sepsis.
ABT Innovations Inc.'s peptide technology covers a broad range of therapeutic applications, including bacterial biofilm infections anti-inflammatories, anti-infective immune modulators, and vaccine adjuvants.